Pfizer Inc. $PFE Stock Holdings Boosted by Canada Post Corp Registered Pension Plan

Key Points

• Canada Post Corp Registered Pension Plan increased its Pfizer stake by 13.8% in the fourth quarter, adding 47,286 shares and bringing its total holdings to 390,128 shares worth about $9.7 million.
• Pfizer posted a mixed but generally positive quarterly update, beating earnings and revenue estimates for Q1 while also guiding FY2026 EPS at $2.80-$3.00. The company’s revenue rose 5.4% year over year, but shares still fell 1.7% amid broader concerns.
• Key catalysts include a Europe label expansion for hemophilia drug Hympavzi and continued pipeline activity across migraine, RSV, and other programs. At the same time, investors remain wary of declining COVID-related sales and looming patent expirations.

Canada Post Corp Registered Pension Plan increased its position in Pfizer Inc. (NYSE:PFE - Free Report) by 13.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 390,128 shares of the biopharmaceutical company's stock after acquiring an additional 47,286 shares during the period. Canada Post Corp Registered Pension Plan's holdings in Pfizer were worth $9,714,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC grew its stake in shares of Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after purchasing an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC raised its stake in shares of Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after purchasing an additional 2,087 shares in the last quarter. United Bank raised its stake in shares of Pfizer by 12.4% during the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company's stock valued at $1,408,000 after purchasing an additional 6,415 shares in the last quarter. Sei Investments Co. lifted its holdings in Pfizer by 31.5% in the second quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company's stock worth $63,889,000 after purchasing an additional 631,523 shares during the period. Finally, HUB Investment Partners LLC grew its position in Pfizer by 45.3% in the 2nd quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company's stock valued at $2,480,000 after buying an additional 31,896 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced a Europe label expansion for its hemophilia therapy Hympavzi, which could broaden the drug’s commercial opportunity and support long-term revenue growth.
• Positive Sentiment: Multiple updates highlighted ongoing clinical and development activity, including a new Korea migraine study for Nurtec ODT, a Phase 1 food-effect study for PF-07799933, a prazosin site-transfer trial, and a planned Japan RSV vaccine trial. These reinforce Pfizer’s pipeline and global expansion efforts.
• Positive Sentiment: Recent commentary around Pfizer’s Q1 earnings pointed to improving momentum in new and acquired products, especially oncology and migraine treatments, as well as progress from the Seagen integration and legal settlements that may improve clarity around future cash flow.
• Neutral Sentiment: Media coverage also noted that investor sentiment remains mixed, with some analysts and commentators arguing Pfizer still lacks strong earnings momentum and is being supported more by its dividend and defensive valuation than by a clear near-term growth catalyst.
• Negative Sentiment: Pfizer continues to face concerns about declining COVID-related sales and looming patent expirations, which have weighed on the stock even after earnings beat expectations.

Pfizer Stock Down 1.7%

Shares of Pfizer stock opened at $25.31 on Friday. Pfizer Inc. has a 1 year low of $22.45 and a 1 year high of $28.75. The company has a market cap of $144.25 billion, a P/E ratio of 19.32 and a beta of 0.35. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The stock has a 50-day moving average price of $26.98 and a 200 day moving average price of $26.19.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion for the quarter, compared to analysts' expectations of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business's revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts expect that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.8%. The ex-dividend date is Friday, May 8th. Pfizer's dividend payout ratio is currently 131.30%.

Analyst Ratings Changes

Several brokerages recently commented on PFE. Barclays began coverage on Pfizer in a report on Thursday, February 19th. They set an "underweight" rating and a $25.00 target price on the stock. Bank of America decreased their target price on Pfizer from $27.00 to $26.00 and set a "neutral" rating for the company in a research note on Thursday, April 9th. Argus upgraded shares of Pfizer from a "hold" rating to a "buy" rating and set a $35.00 price target on the stock in a research report on Monday, March 2nd. Royal Bank Of Canada reissued an "underperform" rating and issued a $25.00 price target on shares of Pfizer in a report on Monday, April 20th. Finally, Guggenheim raised their price objective on shares of Pfizer from $35.00 to $36.00 and gave the company a "buy" rating in a research report on Tuesday, March 24th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $28.84.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.